TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22487001
Drug: Parnaparin 8500
Normalized name: parnaparin
DrugBank: Parnaparin (DB09260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin 8500 UI once daily for 10 days followed by placebo for 20 days (group A)
Study: 22487001
Drug: Parnaparin 8500
Normalized name: parnaparin
DrugBank: Parnaparin (DB09260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin 8500 UI once daily for 10 days followed by 6400 UI once daily for 20 days (group B)
Study: 22487001
Drug: Parnaparin 4250
Normalized name: parnaparin
DrugBank: Parnaparin (DB09260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin 4250 UI once daily for 30 days (group C)
Study: 20517641
Drug: Buspirone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (0.5 mg/kg/day)
Study: 20517641
Drug: Methylphenidate (0.3-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3-1 mg/kg/day)
Study: 15127961
Drug: Granisetron (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (10 microg/kg or 1 mg)
Study: 7646913
Drug: Subcapsular orchiectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcapsular orchiectomy plus oral hydrocortisone and bromocriptine (arm 3)
Study: 2676529
Drug: Oral controlled-release
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral controlled-release morphine (30 mg)
Study: 25483694
Drug: Bivalent Staphylococcus
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent Staphylococcus aureus glycoconjugated vaccine (2 doses)
Study: 19168553
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose MDMA (1.0 mg/kg)
Study: 19168553
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose MDMA (1.6 mg/kg)
Study: 11833048
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g sucrose with a moderate fat load
Study: 11833048
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g glucose with a moderate fat load
Study: 10084100
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms kg-1 morphine
Study: 29029896
Drug: Clemastine fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine fumarate (5·36 mg orally twice daily) for 90 days
Study: 29029896
Drug: Clemastine fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine fumarate (5·36 mg orally twice daily) for 60 days
Study: 23415431
Drug: Hazelnut-enriched diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hazelnut-enriched diet (4 weeks; hazelnut contributing 18%-20% of total daily energy intake)
Study: 21240901
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) 15 μg daily
Study: 15355147
Drug: Similarity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similarity of solution tool
Study: 9481031
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (10 mL daily)
Study: 9481031
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (10 mL daily)
Study: 7817456
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A and megadose multivitamins in combination with intravesical BCG
Study: 6187790
Drug: Compound 48/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound 48/80
Study: 2918185
Drug: Antigen vs
Normalized name: Blood group antigen VS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigen vs Compound 48/80
Study: 17361529
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine plus Xin'anning Nasal Drop (XAND)
Study: 12598392
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group received videotapes and a brochure designed to review skills for self control and treatment
Study: 12598392
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received traditional treatment only
Study: 7040657
Drug: Saline flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline flush following diazepam administration
Study: 7040657
Drug: Barbotage (diluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbotage (diluting the drug with the patient's own blood before injection)
Study: 31035117
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone gel (8%, 90 mg) once daily
Study: 31035117
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (progesterone oil) once daily
Study: 31035117
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone gel and Intramuscular progesterone
Study: 23830936
Drug: Once-weekly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly resistance training (1x RT)
Study: 23830936
Drug: Twice-weekly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly resistance training (2x RT)
Study: 23830936
Drug: Twice-weekly balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly balance and tone training (BAT)
Study: 22137075
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/d) with cilostazol (200 mg/d) for 14 days (group 3)
Study: 22137075
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/d) for 14 days (group 1)
Study: 22137075
Drug: High-maintenance dose
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-maintenance dose of clopidogrel (150 mg/d) for 14 days (group 2)
Study: 22137075
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/d) for 14 days (control group)
Study: 17971943
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 10 mg/d for 48 weeks
Study: 11791956
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) 25 mg/kg
Study: 11791956
Drug: Mefloquine (MQ)
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefloquine (MQ) 15 mg/kg
Study: 20813217
Drug: MF59-adjuvanted influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted influenza vaccine
Study: 10930676
Drug: Unadjuvanted subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unadjuvanted subunit influenza vaccine
Study: 9065352
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray (256 micrograms/day)
Study: 9065352
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray (400 micrograms/day)
Study: 8417382
Drug: No calcium-channel
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No calcium-channel blocker
Study: 22228743
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (ALA) 600 mg once daily for 5 weeks
Study: 8926604
Drug: Drug trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug trials
Study: 10487503
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg daily for 12 weeks)
Study: 30236238
Drug: sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 4 mg kg‐1
Study: 30236238
Drug: sugammadex 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 16 mg kg‐1
Study: 17305661
Drug: Prednisolone 1
Normalized name: prednisolone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1 mg/kg
Study: 12728539
Drug: troglitazone 200
Normalized name: troglitazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: troglitazone 200 mg/day
Study: 8741948
Drug: Alcohol pretreatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol pretreatment (0.5 g/kg and 1.0 g/kg)
Study: 1414040
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg methotrexate (MTX) administered intramuscularly once a week
Study: 1414040
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg gold sodium thiomalate (GST) administered intramuscularly once a week
Study: 12207634
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg methotrexate (MTX)
Study: 1749945
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg gold sodium thiomalate (GST)
Study: 2580179
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg + hydrochlorothiazide (HCTZ) 25 mg twice a day
Study: 2580179
Drug: High-dose captopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose captopril (3 X 50-3 X 150 mg, mean = 325 +/- 87 mg/day) changed to low-dose captopril (2 X 50 mg, mean = 96 +/- 14 mg/day) in a fixed combination with 25 mg HCTZ
Study: 29726361
Drug: 0.1% mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% mometasone furoate (MF) cream applied twice daily from day 1 of PMRT to 14 days after PMRT
Study: 29726361
Drug: Eucerin Original
Normalized name: Eucerin Original Healing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucerin Original (E) cream applied twice daily from day 1 of PMRT to 14 days after PMRT
Study: 29726361
Drug: Eucerin Original
Normalized name: Eucerin Original Healing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucerin Original (E) cream
Study: 24932565
Drug: Marriage Checkup
Normalized name: Cardui Mariae Fructus
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marriage Checkup (MC) treatment
Study: 10453872
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone for 3 months (20 mg/d for 8 weeks, 15 mg/d for 2 weeks, and 10 mg/d for 2 weeks) followed by inhaled budesonide (800 microg bid for 15 months)
Study: 11796428
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets followed by placebo inhaler therapy
Study: 2334037
Drug: 16 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 ml/kg of Ringer's acetate solution immediately before spinal anaesthesia (Group A)
Study: 2334037
Drug: 8 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml/kg of Ringer's acetate solution immediately before spinal anaesthesia (Group B)
Study: 498720
Drug: Smoking MH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking MH containing 7.5 mg (‐) delta‐9‐tetrahydrocannabinol
Study: 31828315
Drug: Complete substitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete substitution of cigarettes with nicotine gum or lozenge (CS‐NRT)
Study: 12860492
Drug: Fast-disintegrating oral
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-disintegrating oral risperidone tablet (0.5 mg)
Study: 12860492
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral risperidone tablet (0.5 mg)
Study: 12860492
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (fast-disintegrating and conventional)
Study: 10530501
Drug: Bio‐Quinone Q10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio‐Quinone Q10 (100 mg) with Bio‐Antox (n = 13, group 2)
Study: 8656146
Drug: Methimazole 10
Normalized name: methimazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole 10 mg every 12th h
Study: 8656146
Drug: Propylthiouracil 100
Normalized name: propylthiouracil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil 100 mg every 12th h
Study: 8656146
Drug: Methimazole 10
Normalized name: methimazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole 10 mg every 8th h
Study: 8656146
Drug: Propylthiouracil 100
Normalized name: propylthiouracil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil 100 mg every 8th h
Study: 8656146
Drug: Methimazole 10
Normalized name: methimazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole 10 mg every 6th h
Study: 8656146
Drug: Propylthiouracil 100
Normalized name: propylthiouracil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil 100 mg every 6th h
Study: 6509781
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of T3 therapy (20 micrograms twice a day)
Study: 20807892
Drug: Once-weekly bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly bortezomib
Study: 20807892
Drug: Twice-weekly bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly bortezomib
Study: 16342083
Drug: Isokinetic exercise,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isokinetic exercise, pulse ultrasound, and intraarticular hyaluronan therapy
Study: 10400483
Drug: Aspirin intolerance
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin intolerance
Study: 7759787
Drug: Clonidine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.04 mg/m2 body surface twice daily for 12 months)
Study: 321182
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine dental gel
Study: 321182
Drug: Placebo quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo quinine sulfate-containing gel
Study: 25770117
Drug: pCMV-vegf165 intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: pCMV-vegf165 intramuscular injections (1.2 mg, 2 injections, 14 days apart) with standard pharmacological treatment
Study: 25770117
Drug: pCMV-vegf165 intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: pCMV-vegf165 intramuscular injections
Study: 24187867
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment according to the Global Initiative for Asthma scheme
Study: 17576863
Drug: Pulse steroids
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse steroids in addition to standard intravenous immunoglobulin
Study: 2607058
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 5 mg, 10 mg, 15 mg, and 20 mg
Study: 1110481
Drug: 5 per
Normalized name: 25 Person ANSI KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 per cent dextrose in normal saline infusions
Study: 31015560
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (verbal suggestion that treatment was effective)
Study: 31015560
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (told that treatment was inert)
Study: 21750358
Drug: HiToP (High
Approvals — FDA: no, EMA: no, PMDA: no
Description: HiToP (High Tone Power Therapy)
Study: 18853250
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (500 mg of elemental calcium as calcium carbonate plus 200 IU of vitamin D(3) twice daily)
Study: 18853250
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (1,000 mg of elemental calcium as calcium carbonate plus 400 IU of vitamin D(3) daily)
Study: 23285154
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral doxycycline twice a day for 30 days
Study: 16019766
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (local surface anesthesia)
Study: 16019766
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (control)
Study: 12718836
Drug: GSK MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK MMR vaccine (three lots), 125 subjects each lot
Study: 12718836
Drug: GSK MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK MMR vaccine
Study: 12718836
Drug: Merck MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain Injection [Varivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merck MMR vaccine, 125 subjects
Study: 12718836
Drug: GSK MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK MMR vaccine and Merck MMR vaccine
Study: 9449500
Drug: Active challenge
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active challenge with a single-dose drink equivalent to 300 ml of cow's milk
Study: 9449500
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (cow's milk)
Study: 9449500
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active and placebo treatments
Study: 8595072
Drug: Percutaneous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Percutaneous ibuprofen gel (500 mg, 10 g 5% gel on the back, area of 20 x 20 cm) with occlusion for 2 h
Study: 8595072
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen tablet (400 mg)
Study: 389050
Drug: LRH (Luteinizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRH (Luteinizing Hormone-Releasing Hormone)
Study: 11811223
Drug: Cisapride 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.2 mg/kg (max 5mg/dose) plus MgO for 4 weeks
Study: 11811223
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (MgO) alone (125 mg three times a day for <20 kg or 250 mg three times a day for >20 kg)
Study: 11811223
Drug: Cisapride 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.2 mg/kg (max 5mg/dose) plus MgO for 1 week
Study: 30745518
Drug: Fosravuconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosravuconazole (100 mg, orally once a day for 12 weeks)
Study: 26209166
Drug: Eldecalcitol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldecalcitol at 0.75 μg/day and alendronate at 35 mg/week
Study: 26209166
Drug: Alendronate at
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate at 35 mg/week
Study: 25385669
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone in oil (PIO)
Study: 16319891
Drug: Salmeterol (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (long-acting bronchodilator)
Study: 16319891
Drug: Albuterol (short-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (short-acting beta2-agonist bronchodilator)
Study: 12487223
Drug: Fexofenadine 180
Normalized name: fexofenadine 180 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 180 mg orally daily for 1 week
Study: 7628834
Drug: Diltiazem sustained-release
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem sustained-release (Mono-Tildiem LP 300 mg) with food intake
Study: 7628834
Drug: Diltiazem sustained-release
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem sustained-release (Mono-Tildiem LP 300 mg) without food intake
Study: 7628834
Drug: Diltiazem sustained-release
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem sustained-release (Mono-Tildiem LP 300 mg) at different times of administration
Study: 3450519
Drug: Nifedipine therapy
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine therapy
Study: 28559255
Drug: MHAB5553A (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAB5553A (120 mg)
Study: 28559255
Drug: MHAB5553A (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAB5553A (1,200 mg)
Study: 28559255
Drug: MHAB5553A (3,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAB5553A (3,600 mg)
Study: 28559255
Drug: MHAB5553A (8,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAB5553A (8,400 mg)
Study: 28559255
Drug: MHAB5553A (10,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAB5553A (10,800 mg)
Study: 25062086
Drug: Myorelaxation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myorelaxation Therapy (nocturnally applied non-occluding sublingual relaxation splint combined with daily stretching exercises)
Study: 21774822
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg daily; n = 28)
Study: 10563276
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (0.3 cc metaproterenol in 2.5 cc of saline at times 0, 20", 40", 1', 2', 3', 4', 5', 6', and 7')
Study: 8939269
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a solution of purified and biologically standardized extract of Parietaria judaica, following a preseasonal rush schedule.
Study: 8939269
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (symptomatic drugs only)
Study: 1767322
Drug: Cerebrolysin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (15 ml of the drug in 200 ml of a 0.85% NaCl solution: 10 ml in the morning and 5 ml in the evening)